EUVIMEDEUVIMED entdecken
Übersichtsarbeit

Targeting phosphodiesterase 4 as a potential therapy for Parkinson’s disease: a review

Pooja Devi Nongthombam, Reena Haobam

Molecular Biology Reports · 2024

DOI: 10.1007/s11033-024-09484-8 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Molecular Biology Reports, 2024. Verfasst von Pooja Devi Nongthombam und 1 weiteren Autor:innen. Beteiligte Einrichtung: Department of Biotechnology, Manipur University, Canchipur, Imphal, 795003, India. Hauptthemen laut MEDLINE: Parkinson Disease, Phosphodiesterase 4 Inhibitors, Neurodegenerative Diseases. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 102 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Phosphodiesterases (PDEs) have become a promising therapeutic target for various disorders. PDEs are a vast and diversified family of enzymes that degrade cyclic adenosine monophosphate (cAMP) and cyclic guanosine monophosphate (cGMP), which have several biochemical and physiological functions. Phosphodiesterase 4 (PDE4) is the most abundant PDE in the central nervous system (CNS) and is extensively expressed in the mammalian brain, where it catalyzes the hydrolysis of intracellular cAMP. An alteration in the balance of PDE4 and cAMP results in the dysregulation of different biological mechanisms involved in neurodegenerative diseases. By inhibiting PDE4 with drugs, the levels of cAMP inside the cells could be stabilized, which may improve the symptoms of mental and neurological disorders such as memory loss, depression, and Parkinson's disease (PD). Though numerous studies have shown that phosphodiesterase 4 inhibitors (PDE4Is) are beneficial in PD, there are presently no approved PDE4I drugs for PD. This review presents an overview of PDE4Is and their effects on PD, their possible underlying mechanism in the restoration/protection of dopaminergic cell death, which holds promise for developing PDE4Is as a treatment strategy for PD. Methods on how these drugs could be effectively delivered to develop as a promising treatment for PD have been suggested.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Parkinson DiseasePhosphodiesterase 4 InhibitorsNeurodegenerative DiseasesAnimalsHumansCyclic Nucleotide Phosphodiesterases, Type 4Cyclic AMPCyclic GMPMammalsDiethylstilbestrol

Stichwörter der Autor:innen

ApoptosisNeurodegenerationNeuroinflammationOxidative stressPhosphodiesterase 4 inhibitors

Substanzen

Cyclic Nucleotide Phosphodiesterases, Type 4diethylstilbestrol monophosphatePhosphodiesterase 4 InhibitorsCyclic AMPCyclic GMPDiethylstilbestrol

Autor:innen und Institutionen

  • Department of Biotechnology, Manipur University, Canchipur, Imphal, 795003, India.
  • Department of Biotechnology, Manipur University, Canchipur, Imphal, 795003, India. reena_haobam@rediffmail.com.

Zitieren

APA

Nongthombam, P. D., & Haobam, R. (2024). Targeting phosphodiesterase 4 as a potential therapy for Parkinson’s disease: a review. Molecular Biology Reports. https://doi.org/10.1007/s11033-024-09484-8

Vancouver

Nongthombam PD, Haobam R. Targeting phosphodiesterase 4 as a potential therapy for Parkinson’s disease: a review. Molecular Biology Reports. 2024. doi:10.1007/s11033-024-09484-8

BibTeX
@article{Nongthombam2024,
  author = {Nongthombam, Pooja Devi and Haobam, Reena},
  title = {Targeting phosphodiesterase 4 as a potential therapy for Parkinson’s disease: a review},
  journal = {Molecular Biology Reports},
  year = {2024},
  doi = {10.1007/s11033-024-09484-8}
}
Kostenlos starten →